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Inhibitory Potencies of Several Iridoids on Cyclooxygenase-1,
Cyclooxygnase-2 Enzymes Activities, Tumor Necrosis factor-a
and Nitric Oxide Production In Vitro
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Natural Products Research Institute, College of Pharmacy, Seoul National University, 28-Yungun-dong,
Jongro-ku, Seoul 110-460, Korea
To verify the anti-inflammatory potency of iridoids, seven iridoid glucosides (aucubin, catalpol,
gentiopicroside, swertiamarin, geniposide, geniposidic acid and loganin) and an iridoid aglycone
(genipin) were investigated with in vitro testing model systems based on inhibition of
cyclooxygenase (COX)-1/-2 enzymes, the tumor necrosis factor-a (TNF-a) formation and
nitric oxide (NO) production. The hydrolyzed-iridoid products (H-iridoid) with b-gludosidase
treatment only showed inhibitory activities, and revealed different potencies, depending on their
chemical structures. Without the b-gludosidase treatment, no single iridoid glycoside exhibited
any activities. The aglycone form (genipin) also did not show inhibitory activities. To compare
anti-inflammatory potency, the inhibitory concentrations (IC50) in each testing system were
measured. The hydrolyzed-aucubin product (H-aucubin) with b-gludosidase treatment showed
a moderate inhibition on COX-2 with IC50 of 8.83mM, but much less inhibition (IC50, 68.9 mM)
on COX-1 was noted. Of the other H-iridoid products, the H-loganin and the H-geniposide
exhibited higher inhibitory effects on COX-1, revealing IC50 values of 3.55 and 5.37mM,
respectively. In the case of TNF-a assay, four H-iridoid products: H-aucubin, H-catalpol,
H-geniposide and H-loganin suppressed the TNF-a formation with IC50 values of 11.2, 33.3,
58.2 and 154.6mM, respectively. But other H-iridoid products manifested no significant activity.
Additional experiments on NO production were conducted. We observed that only the
H-aucubin exhibited a significant suppression with IC50 value of 14.1mM. Genipin, an agycone
form, showed no inhibitory effects on all testing models, implying the hydrolysis of the
glycosidic bond of iridoid glycoside is a pre-requisite step to produce various biological
activities.
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Introduction
Iridoids represent a group of natural constituents with a
monoterpene cyclic ring. They exist usually as glycosidic
forms in nature, but are also found on rare occasions as
an aglycone. Iridoids manifest dual facets of biological
activities; one is to act as a defensive substance for
certain plant species (1, 2), and the other is to produce
a variety of pharmacological actions for animals.
Many medicinal plants containing iridoids such as
Plantago, Cornus, Rehmanniae, Scrophularia, Gentiana
and Harpagophytum have long been used to treat various
ailments in the East and the West. The pharmacological
activities are summarized: treatment of hepatic dysfunc-
tion (3), stimulation of bile acid excretion (4), antimicro-
bial activities (5), antitumor activities (6), antidotal
activities for noxious Amanita mushroom poisoning (7),
antiviral activities against Hepatitis B virus (8) and
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properly cited.anti-inflammatory activities (9). A variety of iridoids
including Scropolioside A, scrovalentinoside, verminoside
and ipolamiide have been reported to possess significant
anti-inflammatory activities in vitro and/or in vivo assay
systems.
The present study is aimed to verify the anti-
inflammatory potency of seven iridoid glucosides, and
an aglycone form. Additional test samples derived from
iridoid glycosides were also prepared by treating those
seven iridoid glycosides with b-gludosidase: they are
called the hydrolyzed-iridoid products (H-iridoid). Since
our previous study (10) indicated that an iridoid glyco-
side, namely, aucubin exhibited various biological activ-
ities in vitro as it was treated with b-gludosidase to
produce its hydrolyzed product (H-aucubin). As with the
assay systems of anti-inflammatory activities, measure-
ments of cyclooxygenases (COX-1 and COX-2) enzymes
activities, tumor necrosis factor-a (TNF-a) formation and
nitric oxide (NO) production were conducted in vitro.
In addition, the inhibition concentration (IC50) of each
test sample was calculated to compare its potency.
Methods
Materials
Seven iridoid glucosides, namely, aucubin (99.5%),
catalpol (>98%), loganin (>98%), gentiopicroside
(>98%), swertiamarin (>98%), geniposide (99%), geni-
posidic acid (>98%) and one genin, genipin (>98%),
were purchased from Wako Pure Chemical Industries,
Ltd. (Osaka, Japan) (Fig. 1). Aspirin, piroxicam,
meloxicam, rolipram, N-nitro-L-arginine methyl ester
(L-NAME), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide (MTT), a lipopolysaccharide (LPS)
(from Escherichia coli, 011: B4), arachidonic acid (AA),
Griess reagent and b-glucosidase (EC 3.2.1.21) were
obtained from Sigma Chemical Co. (St Louis, MO,
USA). DMEM (Dulbecco’s Modified Eagle’s Medium)
and RPMI1640 (Roswell Park Memorial Institute)
medium and other reagents for cell cultures were
obtained from Gibco BRL Life Biotechnologies
(Gaithersburg, MD, USA). Enzyme-linked immunosor-
bent assays (ELISA) kits for the determination of PGE2
(prostaglandin E2) and TXB2 (thromboxane B2) were
obtained from Cayman Chemical Co. (Ann Arbor, MI,
USA). An interferon (INF)-g, antimouse TNF-a mono-
clonal antibodies and a biotinylated secondary antibody
were purchased from Pharmingen International (San
Diego, CA, USA).
MTT Cell Viability Assay
The degree of mitochondrial respiration as an indica-
tor of cell viability was assayed by measuring the
mitochondria-dependant reduction of MTT to produce
formozan crystals. Absorbance levels due to color
changes were measured at 450 and 650nm using the
Automatic ELISA microplate reader (EL808, Bio-Tek
Instrument Inc). Details of this experiment were reported
previously (10).
Cyclooxygenase-1(COX-1) Assay using Human
Erythroleukemia (HEL) Cells
The COX-1 assay with HEL cells (American Type
Culture Collection, ATCC) was carried out using the
method of Berg et al. (11). Briefly describing the culture
condition: HEL 92.1.7 cells were grown in RPMI 1640
supplemented with a 10% heat-inactivated fetal bovine
serum (HyClone) under 5% CO2. Penicillin (100U/ml)
and streptomycin (100mg/ml) were added to the culture
medium. Then cells were harvested and re-suspended in
a fresh medium at 1 10
7cells/ml. The stock solutions of
test compounds dissolved in DMSO were diluted with the
medium just before the tests. A portion of cell suspension
(500ml) was added to the testing sample solution (250ml
each), mixed and incubated for 30min at 37 C. Then, AA
was added to a final concentration of 30mM, and
incubated for an additional 15min at 37 C. The reaction
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Figure 1. Chemical structures of iridoids tested.
42 Inhibitory potencies of iridoidswas stopped by centrifugation (900rpm) for 5min at 4 C.
To prepare the H-iridoid products, 1mM of each iridoid
glucoside was pre-incubated with the same volume of
0.5mM of b-glucosidase (iridoid: enzyme=1.0:0.5v/v),
and diluted by adding distilled water to the specified
concentrations. Under this condition, almost all iridoid
glycosides were easily converted by b-glucosidase into
their hydrolyzed products (12). The concentration of
TXB2 in the supernatant was measured by using the
ELISA method.
COX-2 Assay using RAW 264.7 Cells
A murine macrophage cell line, RAW 264.7 cells
(ATCC), was maintained at 37 C in DMEM medium
(Gibco BRL) containing 10% fetal calf serum, 2mM
L-glutamine, penicillin (100U/ml) and streptomycin
(100mg/ml). Cells were cultured at a density of approxi-
mately 2 10
5 cells/ml, then harvested and re-suspended
in a fresh medium at a concentration of 1 10
6 cells/ml.
Immediately after adding hydrolyzed-iridoid samples
(H-iridoids), the cells were incubated for 30min at
37 C. Then the cells were stimulated with LPS (final
concentration of 1mg/ml) and incubated for an additional
6h. Thereafter, similar assaying procedures were followed
as done in COX-1 assay using HEL cells. However,
instead of adding TXB2, PGE2 was added to the testing
solutions, and the PGE2 concentration in the supernatant
was measured using the ELISA method.
Assay of TNF-a Formation
RAW 264.7 cells (2.5 10
5 cells/well) were treated with
LPS/IFN-g in the presence or the absence of the testing
iridoid samples for 4h, and the assay was performed as
described previously (10).
Assay of NO Production
Accumulated concentrations of NO2
  in the medium
were measured as an indicator of NO production. The
assay procedure was the same as described previously
(13). Briefly, RAW 264.7 cells were plated each at
a concentration of 1.5 10
6 cells/ml and stimulated
with LPS in the presence or the absence of the testing
iridoid samples for 24h. Each separated supernatant
was mixed with an equal volume of Griess reagent
(1% sulfanilamide, 0.1% naphthylethylenediamine dihy-
drochloride and 2% phosphoric acid) and incubated at
room temperature in the dark for 10min. The production
of NaNO2 was measured at 550nm.
Statistics
Data expressed as the mean standard deviation were
obtained from three or four separate experiments.
Statistical analysis of the data was performed by one-
way analysis of variances followed by Dunnett’s test.
Values of P<0.05 were considered statistically signifi-
cant. Each IC50 value was calculated by non-linear
regression analysis (14).
Results
Effects on Cell Viability
Cell viability tests were performed throughout all
experiments by using the MTT assay. In all iridoid test
samples including H-iridoids at a concentration up to
100mM, no significant cytotoxicity was observed (data
not shown).
Inhibitory Activities on COX-1 Enzyme
To examine potential inhibitory activities of iridoid
samples on COX-1, the amounts of TXB2 reduction
were measured in intact HEL cell culture (Table 1). The
aspirin, a typical non-steroidal, anti-inflammatory drug,
and the piroxicam, a specific COX-1 inhibitor, were
employed as positive control drugs. Both control drugs
showed inhibitory activities on COX-1 assay in dose-
dependant manner with IC50 of 7.23 and 0.31mM,
respectively (Table 2). None of iridoid glycosides without
pre-treating b-glucosidase exhibited any significant inhib-
itory activities on COX-1 assay. Of those iridoid glyco-
sides which were pre-treated with b-glucosidase, both
H-geniposide and H-loganin produced high inhibitory
activities on COX-1 assay, revealing IC50 values of 5.37
and 3.55mM, respectively. The H-aucubin showed an
IC50 value of 68.9mM, indicating relatively less potency
than H-geniposide and H-loganin. Other H-iridoid
samples and genipin (aglycone) exhibited no significant
inhibitory activities on COX-1 assay.
Table 1. Inhibition of TXB2 (thromboxane B2) formation in intact HEL
cells by hydrolyzed-iridoids (H-iridoids)
Test sample 1mM1 0 mM5 0 mM 100mM
H-aucubin 101.3 3.0 97.6 6.4 84.0 4.5 68.6 3.0
y
H-catalpol 101.3 3.0 91.3 5.0 94.0 9.5 92.0 4.0
H-loganin 91.0 2.6 57.6 5.5* 55.0 5.2* 46.6 6.4*
H-gentiopicroside 101.3 3.0 90.0 3.4 92.0 8.5 88.6 3.0
H-swertiamarin 98.0 6.0 88.6 5.1 89.0 7.0 91.6 8.1
H-geniposide 91.6 2.5 67.3 3.0* 54.6 9.5* 51.6 3.2*
H-geniposidic acid 91.6 6.5 92.0 8.5 92.3 5.6 89.0 3.6
genipin 88.3 5.3 86.6 4.2 84.0 7.0 88.3 6.1
Values are presented as mean SD of the percentage of TXB2
formation of cultures treated with vehicle (DMSO) only.
*Statistically significant difference: P<0.05.
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Experiments using LPS-stimulated RAW 264.7 cells were
conducted to examine inhibitory activities on COX-2 as
described in Methods; the formation of the PGE2 was
measured and data were shown in Table 3. Both aspirin
and meloxicam were used as positive control drugs for
COX-2 inhibitors. Both control drugs exhibited inhibi-
tory activities in dose-dependant manner with IC50 of
14.2 and 0.16mM, respectively (Table 2). Contrary to the
data obtained from COX-1 assay, we observed that
H-aucubin exhibited a higher inhibition on COX-2 assay
(IC50 value of 8.83mM); whereas H-geniposide and
H-loganin, produced much less inhibition with IC50
values of 32.4 and 131.0mM, respectively.
Suppression of TNF-a Formation
The assay was performed by using an ELISA method in
RAW 264.7 cells that were stimulated with LPS/IFN-g as
described in Methods. The rolipram, a positive control
drug, suppressed the TNF-a formation by 86% even at
a concentration of 1mg/ml. Unlike those results obtained
from COX-1/-2 experiments, suppression of TNF-a
formation was apparently more sensitive to a variety of
testing iridoids as noted as four H-iridoid samples,
H-aucubin, H-catalpol, H-geniposide and H-loganin,
showed suppressive activities with IC50 values of 11.2,
33.3, 58.2 and 154.6mM, respectively (Tables 2 and 4).
Other H-iridoids and genipin did not have much
influence on the suppression of TNF-a formation.
Suppression of NO Production
To examine suppressive activities of H-iridoids on NO
production, the LPS-stimulated RAW 264.7 cells were
used (Table 5). The L-NAME, a well-known inhibitor,
was used as a positive control. Treatments of L-NAME
suppressed significantly the NO production in dose-
dependant manners with an IC50 value of 14.4mM
(Table 2). Of H-iridoid samples tested so far, only
H-aucubin exhibited a significant suppression with an
Table 5. Inhibition of NO (nitric oxide) production in LPS-stimulated
RAW264.7 cells by hydrolyzed-iridoids (H-iridoids)
Test sample 1mM1 0 mM5 0 mM 100mM
H-aucubin 96.3 7.4 71.3 9.0* 49.0 9.8* 40.0 3.6*
H-catalpol 96.0 4.0 87.0 7.2 86.0 8.8 85.3 5.9
H-loganin 93.3 6.1 98.0 8.5 95.6 9.2 105.3 6.5
H-gentiopicroside 103.3 6.5 95.6 6.4 94.6 4.7 96.0 7.9
H-swertiamarin 96.3 9.2 89.0 5.1 84.6 14.5 84.2 7.9
H-geniposide 95.3 5.0 89.3 6.6 101.3 9.0 104.6 7.2
H-geniposidic acid 94.3 6.6 93.6 2.3 86.0 7.9 98.3 8.7
genipin 104.6 8.8 105.2 10.0 111.3 11.0 106.3 13.4
Values are presented as mean SD of the percentage of NO production
of cultures treated with vehicle (DMSO) only.
*Statistically significant difference: P<0.05.
Table 2. IC50 values of positive controls and hydrolyzed-iridoids
(H-iridoids) for the inhibition of COX-1/-2 enzymes activities, the
formation of TNFa and the production of NO
COX-1 (mM) COX-2 (mM) TNFa (mM) NO (mM)
Aspirin 7.23 14.2 – –
Piroxicam 0.31 – – –
Meloxicam – 0.16 – –
Rolipram – – 0.11
L-NAME – – – 14.4
H-Aucubin 68.9 8.83 11.2 14.1
H-Catalpol ND ND 33.3 ND
H-Loganin 3.55 131.0 154.6 ND
H-Geniposide 5.37 32.4 58.2 ND
ND, not determined.
Table 3. Inhibition of PGE2 (prostaglandin E2) formation in LPS-
stimulated RAW264.7 cells by hydrolyzed-iridoids (H-iridoids)
Test sample 1mM1 0 mM5 0 mM 100mM
H-aucubin 92.3 8.5 64.6 6.4* 41.3 8.0* 37.3 4.0*
H-catalpol 88.0 4.0 87.0 7.2 76.0 8.8 75.3 4.9*
H-loganin 93.3 6.1 88.0 8.5 75.6 9.2* 55.3 6.5*
H-gentiopicroside 93.0 6.5 95.6 6.4 84.6 4.7 86.0 7.9
H-swertiamarin 96.3 9.2 89.0 5.2* 84.6 14.5 86.0 7.9
H-geniposide 95.3 5.0 89.3 6.6 71.3 9.0* 64.0 7.2*
H-geniposidic acid 94.3 6.6 93.6 2.3 86.0 7.9 78.0 8.7
genipin 92.3 6.8 90.0 6.2 84.6 7.3 91.3 6.7
Values are presented as mean SD of the percentage of PGE2
formation of cultures treated with vehicle (DMSO) only.
*Statistically significant difference: P<0.05.
Table 4. Inhibition of TNFa (tumor necrosis factor) production in
LPS-stimulated RAW264.7 cells by hydrolyzed-iridoids (H-iridoids)
Test sample 1mM1 0 mM5 0 mM 100mM
H-aucubin 85.6 11.0 63.6 5.5* 44.6 10.5* 24.0 7.9*
H-catalpol 95.6 4.0 92.3 8.0 69.3 6.5* 67.3 8.9*
H-loganin 96.6 4.1 84.6 5.1* 71.0 6.5* 45.3 3.5*
H-gentiopicroside 89.6 4.0 89.0 6.0 82.6 6.6 86.0 6.5
H-swertiamarin 89.6 4.0 93.6 2.0 86.3 4.7 89.3 4.0
H-geniposide 93.3 4.1 88.0 8.5 71.0 3.6* 55.6 4.0*
H-geniposidic acid 100.0 2.0 94.6  12.5 84.0 15.5 82.3 7.3*
genipin 102.3 8.8 97.6 7.3 94.0 9.3 96.6 8.1
Values are presented as mean SD of the percentage of TNFa
production of cultures treated with vehicle (DMSO) only.
*Statistically significant difference: P<0.05.
44 Inhibitory potencies of iridoidsIC50 value of 14.1mM, indicating almost the same
potency as that of the L-NAME treatment. In the view
that the chronic suppression of NO may lead to heart
disease, it is worth investigating the effect of H-aucubin
on the cardiovascular system.
Discussion
Iridoids, naturally occurring substances, are found in
many medicinal herbs including traditional Chinese
herbs. They exist mostly as glycosides and some are
found in genin forms without glycoside moiety in their
structure. Those medicinal plants containing iridoids
show a variety of biological activity as aforementioned.
Of pharmaceutical products as well as dietary supple-
ments containing such medicinal plant materials, agents
(e.g. devil’s claw products made of Harpagophytum) for
treating inflammatory ailments including rheumatic
inflammation have been marketed and used for long
time. To verify the molecular mechanism of anti-
inflammatory activities of iridoid analogs, we carried
out the present study.
Based on the results obtained so far, we confirmed our
previous findings in which iridoid glycoside itself is in
inactive forms, and it should be converted to its active
form by enzymatic hydrolysis of glycosidic bond, leading
to its H-iridoid products (1, 10). Although no definite
structure of H-iridoid products has been determined yet,
it is presumed to produce a cleavage of monoterpene
rings, resulting in the active form of the drug (2, 12). To
support such a postulation, we challenged the genipin
(aglycone) without b-glucosidase treatment into all assay
models in vitro; the animal cells (HEL and RAW 264.7)
do not have b-glucosidase and aglycone form of genipin
is more easily transported into the cell membrane than
iridoid glycosides are. As anticipated, no inhibitory
activities were noted in all three assay models. These
results imply a similar bio-process occurs in whole animal
systems for pharmacological actions of iridoid-containing
herbs. In this connection, it is also mentioned that some
iridoids such as geniposide and gardenoside are converted
to nitrogen-containing metabolites (genipinine and gar-
denine) by intestinal bacterial flora (15). However, it is
uncertain what kinds of biological action can occur with
these genins.
Taking into consideration the structural differences
versus potency of anti-inflammatory activities, only a
minute structural difference renders a marked different
potency to each iridoid. H-geniposide and H-loganin
exhibited high inhibitory potencies on COX-1; whereas
H-aucubin showed very low inhibition on COX-1.
However, H-aucubin produced a moderate inhibition on
COX-2. In addition, H-aucubin only exhibited suppres-
sive activities on both NO production and TNF-a
formation. But H-catalpol, which is a very similar
structure with H-aucubin, revealed no significant inhibi-
tion on COX-1/2 and NO production. In this regard,
further studies are needed with respect to the structural
determination of H-iridoid products. A single medicinal
herb usually contains a mixture of different analogues of
iridoids and different contents of iridoids, depending on
the plant’s parts. Such differences may render different
pharmacological activities to each medicinal herb con-
taining iridoids. Nonetheless, the present study provides
important information for selecting more effective anti-
inflammatory herbs among the many medicinal plants
containing iridoids.
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